PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18398146-2 2008 A plausible candidate is the gene for bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, an essential component of chemotherapy regimens for disseminated testicular germ-cell cancer (TC). Bleomycin 38-47 bleomycin hydrolase Homo sapiens 59-63 18398146-10 2008 CONCLUSION: The homozygous variant G/G of BLMH gene SNP A1450G is associated with reduced survival and higher prevalence of early relapses in TC patients treated with bleomycin-containing chemotherapy. Bleomycin 167-176 bleomycin hydrolase Homo sapiens 42-46 12167044-1 2002 Metabolic inactivation of the antitumor antibiotic bleomycin is believed to be mediated exclusively via the action of bleomycin hydrolase, a cysteine proteinase that is widely distributed in nature. Bleomycin 51-60 bleomycin hydrolase Homo sapiens 118-137 15900213-2 2005 Bleomycin is mainly excreted by the kidneys, but can also be inactivated by bleomycin hydrolase (BMH). Bleomycin 0-9 bleomycin hydrolase Homo sapiens 76-95 15900213-2 2005 Bleomycin is mainly excreted by the kidneys, but can also be inactivated by bleomycin hydrolase (BMH). Bleomycin 0-9 bleomycin hydrolase Homo sapiens 97-100 15900213-5 2005 We investigated the relation between the BMH genotype and the risk of bleomycin-induced pneumonitis (BIP). Bleomycin 70-79 bleomycin hydrolase Homo sapiens 41-44 12167044-2 2002 While the spectrum of antitumor activity exhibited by the bleomycins is believed to reflect the anatomical distribution of bleomycin hydrolase within the host, little has been done to characterize the product of the putative inactivation at a chemical or biochemical level. Bleomycin 58-68 bleomycin hydrolase Homo sapiens 123-142 9855622-1 1998 Bleomycin hydrolase (BH) is a highly conserved cysteine proteinase that deamidates and inactivates the anticancer drug bleomycin. Bleomycin 119-128 bleomycin hydrolase Homo sapiens 0-19 10631140-6 2000 Extending telomerically from the SRO, two additional genes-BLMH, encoding a hydrolase involved in bleomycin resistance, and ACCN1, encoding an amiloride-sensitive cation channel expressed in the CNS-were located in the deleted intervals of seven and three patients, respectively. Bleomycin 98-107 bleomycin hydrolase Homo sapiens 59-63 10404591-2 1999 Although its conserved cellular function is as yet unknown, human bleomycin hydrolase (hBH) has clinical significance in that it is thought to be the major cause of tumor cell resistance to bleomycin chemotherapy. Bleomycin 66-75 bleomycin hydrolase Homo sapiens 87-90 10353821-1 1999 Bleomycin hydrolase (BH) is a cysteine proteinase that inactivates the anticancer drug bleomycin. Bleomycin 87-96 bleomycin hydrolase Homo sapiens 0-19 10353821-1 1999 Bleomycin hydrolase (BH) is a cysteine proteinase that inactivates the anticancer drug bleomycin. Bleomycin 87-96 bleomycin hydrolase Homo sapiens 21-23 9855622-1 1998 Bleomycin hydrolase (BH) is a highly conserved cysteine proteinase that deamidates and inactivates the anticancer drug bleomycin. Bleomycin 119-128 bleomycin hydrolase Homo sapiens 21-23 9331073-1 1997 Bleomycin hydrolase (BH) is the only known eukaryotic enzyme that inactivates the widely used antineoplastic agent bleomycin (BLM) and is a primary candidate gene for protection against lethal BLM-induced pulmonary fibrosis and for BLM resistance in tumors. Bleomycin 115-124 bleomycin hydrolase Homo sapiens 0-19 9485374-1 1998 Bleomycin hydrolase (BH) is unusual among cysteine proteinases because it appears to form multihomomeric structures, inactivates the antitumor glycopeptide bleomycin, and contains a unique C-terminal amino acid sequence. Bleomycin 156-165 bleomycin hydrolase Homo sapiens 0-19 9485374-1 1998 Bleomycin hydrolase (BH) is unusual among cysteine proteinases because it appears to form multihomomeric structures, inactivates the antitumor glycopeptide bleomycin, and contains a unique C-terminal amino acid sequence. Bleomycin 156-165 bleomycin hydrolase Homo sapiens 21-23 9331073-1 1997 Bleomycin hydrolase (BH) is the only known eukaryotic enzyme that inactivates the widely used antineoplastic agent bleomycin (BLM) and is a primary candidate gene for protection against lethal BLM-induced pulmonary fibrosis and for BLM resistance in tumors. Bleomycin 115-124 bleomycin hydrolase Homo sapiens 21-23 7476893-1 1995 Tumor resistance to the glycopeptide anticancer drug bleomycin (BLM) has been suggested to involve metabolic inactivation by BLM hydrolase. Bleomycin 53-62 bleomycin hydrolase Homo sapiens 125-138 34484791-1 2021 The article description and significance to dermatologists: bleomycin flagellate dermatitis is a rare cutaneous manifestation, believed to be due to the lack of bleomycin hydrolase enzyme in the skin, which inactivates bleomycin, resulting in its accumulation. Bleomycin 60-69 bleomycin hydrolase Homo sapiens 161-180 34484791-1 2021 The article description and significance to dermatologists: bleomycin flagellate dermatitis is a rare cutaneous manifestation, believed to be due to the lack of bleomycin hydrolase enzyme in the skin, which inactivates bleomycin, resulting in its accumulation. Bleomycin 219-228 bleomycin hydrolase Homo sapiens 161-180 35467071-1 2022 Human bleomycin hydrolase (hBH) catalyzes deamidation of the anticancer drug, bleomycins (BLM). Bleomycin 78-88 bleomycin hydrolase Homo sapiens 6-25 35467071-1 2022 Human bleomycin hydrolase (hBH) catalyzes deamidation of the anticancer drug, bleomycins (BLM). Bleomycin 78-88 bleomycin hydrolase Homo sapiens 27-30 35467071-1 2022 Human bleomycin hydrolase (hBH) catalyzes deamidation of the anticancer drug, bleomycins (BLM). Bleomycin 90-93 bleomycin hydrolase Homo sapiens 6-25 35467071-1 2022 Human bleomycin hydrolase (hBH) catalyzes deamidation of the anticancer drug, bleomycins (BLM). Bleomycin 90-93 bleomycin hydrolase Homo sapiens 27-30 2506856-1 1989 Bleomycin hydrolase, which hydrolyzes the carboxamide bond in the pyrimidoblamic acid moiety of the bleomycin molecule, also cleaved several p-nitroanilide substrates with a neutral or basic amino acid residue and dipeptide substrates such as L-leucyl-glycine. Bleomycin 100-109 bleomycin hydrolase Homo sapiens 0-19 29730026-0 2018 Activities of recombinant human bleomycin hydrolase on bleomycins and engineered analogues revealing new opportunities to overcome bleomycin-induced pulmonary toxicity. Bleomycin 55-65 bleomycin hydrolase Homo sapiens 32-51 29730026-3 2018 The organ specificity of BLM-induced toxicity has been correlated with the expression of the hBLMH gene, encoding the human bleomycin hydrolase (hBLMH), which is poorly expressed in the lung. Bleomycin 25-28 bleomycin hydrolase Homo sapiens 93-98 29730026-3 2018 The organ specificity of BLM-induced toxicity has been correlated with the expression of the hBLMH gene, encoding the human bleomycin hydrolase (hBLMH), which is poorly expressed in the lung. Bleomycin 25-28 bleomycin hydrolase Homo sapiens 124-143 29730026-3 2018 The organ specificity of BLM-induced toxicity has been correlated with the expression of the hBLMH gene, encoding the human bleomycin hydrolase (hBLMH), which is poorly expressed in the lung. Bleomycin 25-28 bleomycin hydrolase Homo sapiens 145-150 29730026-4 2018 hBLMH hydrolyzes BLMs into the biologically inactive deamido BLMs, thereby protecting organs from BLM-induced toxicity. Bleomycin 17-21 bleomycin hydrolase Homo sapiens 0-5 23076812-0 2012 Action of bleomycin is affected by bleomycin hydrolase but not by caveolin-1. Bleomycin 10-19 bleomycin hydrolase Homo sapiens 35-54 23076812-3 2012 To clarify whether BLH confers the resistance to bleomycin in tumor cells, it is necessary to further investigate the roles of BLH and its combination with other factors such as caveolin-1 in the action of bleomycin. Bleomycin 61-70 bleomycin hydrolase Homo sapiens 19-22 23076812-3 2012 To clarify whether BLH confers the resistance to bleomycin in tumor cells, it is necessary to further investigate the roles of BLH and its combination with other factors such as caveolin-1 in the action of bleomycin. Bleomycin 242-251 bleomycin hydrolase Homo sapiens 19-22 23076812-5 2012 The relationship between action of bleomycin and cellular amount of BLH was detected by the MTT method and western blotting in the human leukemia cell line HL-60, HeLa cervical cancer cells and HaCaT immortalized keratinocyte cells. Bleomycin 47-56 bleomycin hydrolase Homo sapiens 80-83 23076812-6 2012 The sensitivity to bleomycin was increased in HeLa cells after knockdown of BLH mRNA by RNA interference. Bleomycin 19-28 bleomycin hydrolase Homo sapiens 88-91 23076812-8 2012 In addition, regulation of BLH and caveolin-1 expression in HeLa and HaCaT cells was observed in a concentration-dependent manner after exposure to bleomycin. Bleomycin 172-181 bleomycin hydrolase Homo sapiens 27-30 2461572-0 1988 Metabolic inactivation of bleomycin analogs by bleomycin hydrolase. Bleomycin 26-35 bleomycin hydrolase Homo sapiens 47-66 2439200-10 1986 Bleomycin hydrolase activity is low in lungs and skin, the two major sites of normal tissue toxicities, and levels of this enzyme have been elevated in some but not all tumour cell lines selected for resistance to bleomycin. Bleomycin 214-223 bleomycin hydrolase Homo sapiens 0-19 6169344-0 1981 Bleomycin-resistant cells contain increased bleomycin-hydrolase activities. Bleomycin 0-9 bleomycin hydrolase Homo sapiens 44-63 27327270-1 2016 BACKGROUND: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients. Bleomycin 67-76 bleomycin hydrolase Homo sapiens 12-31 27327270-1 2016 BACKGROUND: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients. Bleomycin 67-76 bleomycin hydrolase Homo sapiens 33-37 27327270-1 2016 BACKGROUND: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients. Bleomycin 169-178 bleomycin hydrolase Homo sapiens 12-31 27327270-1 2016 BACKGROUND: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients. Bleomycin 169-178 bleomycin hydrolase Homo sapiens 33-37 27327270-6 2016 CONCLUSION: Besides limitations of the current study, bleomycin pharmacokinetics should be further evaluated in patients with BLMH variations, hence identify those cases even in the frontline setting, where bleomycin should be omitted and replaced with targeted therapy. Bleomycin 54-63 bleomycin hydrolase Homo sapiens 126-130 25101299-5 2014 Two additional strategies were explored to further enhance the cytotoxicity of bleomycin; a novel peptide drug ATX-101 which is known to impair DNA damage responses, and the protease inhibitor E-64 which may reduce bleomycin degradation by inhibition of bleomycin hydrolase. Bleomycin 79-88 bleomycin hydrolase Homo sapiens 254-273 23708668-1 2013 Bleomycin hydrolase (BLH) affects bleomycin chemotherapy through inactivation of bleomycin with deamination. Bleomycin 34-43 bleomycin hydrolase Homo sapiens 0-19 23708668-1 2013 Bleomycin hydrolase (BLH) affects bleomycin chemotherapy through inactivation of bleomycin with deamination. Bleomycin 34-43 bleomycin hydrolase Homo sapiens 21-24 23708668-1 2013 Bleomycin hydrolase (BLH) affects bleomycin chemotherapy through inactivation of bleomycin with deamination. Bleomycin 81-90 bleomycin hydrolase Homo sapiens 0-19 23708668-1 2013 Bleomycin hydrolase (BLH) affects bleomycin chemotherapy through inactivation of bleomycin with deamination. Bleomycin 81-90 bleomycin hydrolase Homo sapiens 21-24 23708668-4 2013 In the present study, we showed that the levels of BLH were significantly reduced during apoptosis induced by the antitumor agents bleomycin, etoposide and hydroxycamptothecin, and inhibited by the caspase inhibitors Q-VD-oph and Z-DEVD-FMK. Bleomycin 131-140 bleomycin hydrolase Homo sapiens 51-54